Delcath’s Hepatic Delivery System Approved in Brazil

Delcath received medical device approval from Brazil’s National Health Surveillance Agency for its Chemosat hepatic delivery system.

The platform delivers chemosaturation therapy to the liver, making it possible to administer melphalan hydrochloride, a chemotherapeutic agent, to the liver while limiting toxicity.

The system isolates the liver’s blood flow using catheters and lowers the agent’s concentration after it leaves the target organ using proprietary filters.